drugset / Trial / NCT04582344

Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)

NCT04582344 ↗

Phase 3 Completed 10214 enrolled Health Institutes of Turkey
RandomizedParallel-groupTriple-blindPrevention

Summary

This study is a randomized, double-blinded, and placebo controlled phase III clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd. The purpose of this study is to evaluate the efficacy, safety and immunogenicity of the experimental vaccine in healthy adults aged 18\~59 Years.

Timeline

Start
2020-09-14
Primary completion
2022-06-30
Completion
2022-07-27

Outcome

Met primary endpoint

paper yielding a vaccine efficacy of 83·5% (95% CI 65·4-92·1; p<0·0001). PMID 34246358 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CoronaVac Vaccine 0.5 ml Intramuscular

Indications